Vantage logo

Six burning Otezla questions

Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.

Vantage logo

Neurocrine voyages into gene therapy 

A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.